Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02389595 · ClinicalTrials.gov registry record

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

A clinical trial of HIV, sponsored by University of Florida.

Active
Registry status
270
Enrollment target
2
Study locations

NCT02389595 is a study of HIV that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 270 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (38% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02389595, a study of HIV, is active but no longer recruiting, sponsored by University of Florida.

ACTIVE NOT RECRUITING
Registry status
270 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection. HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as "effectors" that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate "protective" part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.

Conditions Studied

HIV

Interventions

  • OTHER HIV positive subjects
  • OTHER Non-infected control subjects

Study Locations (2)

Florida

  • University of Florida - Gainesville
  • UF Center for AIDS Research Education and Service - Jacksonville

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2015-05
Est. Completion 2028-05

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02389595

The ClinicalTrials.gov registry entry for NCT02389595 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (38% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which HIV positive subjects is the first listed.

NCT02389595 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02389595 about?

NCT02389595 is a clinical study titled "Selection of a Protective T Cell-based HIV-1/FIV Vaccine". The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been expose...

What is the current status of trial NCT02389595?

This trial is currently active not recruiting. The enrollment target is 270 participants. The study started on 2015-05. Estimated completion is 2028-05.

What conditions does trial NCT02389595 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02389595?

The interventions under investigation include: HIV positive subjects (OTHER), Non-infected control subjects (OTHER).

Who is sponsoring clinical trial NCT02389595?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02389595 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.